The project allows prostate cancer patients to provide their de-identified clinical and genomic data to the research community.
Excluding the sale of the company's colorectal cancer patents to Exact Sciences, its 2017 revenues rose 13 percent.
The updated recommendations discuss testing for DNA repair gene mutations, MSI-H, and dMMR, as well as germline testing and counseling.
A family-based analysis led to an X chromosome variant in MAGEC3 that appeared to contribute to early-onset ovarian cancer risk in sisters and their paternal grandmothers.
The firm has partnered with the University of Surrey to validate and potentially commercialize a test that detects mRNA biomarkers from patient urine samples.
The company discussed its efforts to grow adoption of its products during a call to discuss second quarter financial results for fiscal year 2018.
UgenTec will develop artificially intelligent software to support interpretation of MDxHealth's ConfirMDx and SelectMDx molecular prostate cancer tests.
The coverage decision is based on the results of an evidence development study the companies launched last year.
The company expects to see lower growth in products and services due to timing issues in obtaining billable cases from contracted customers.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.